FDA not heeding advisory committees
Executive Summary
Advisory committee recommendations are not followed by FDA as often as generally thought, Public Citizen asserts in a recent letter in The Lancet. The public interest group claims the agency's regulatory actions were inconsistent with committee recommendations 28 percent of the time based on an analysis of FDA advisory committees from Jan. 1, 1997 through June 30, 2006. The study also finds the frequency of committee meetings prior to approval of new molecular entities declined from 40 and 52 percent in 1998 and 1999 to 24 percent for the 2000-2006 period. FDA's advisory committee process has come under heavy criticism in the past year, with editorials by advisory committee members, a Public Citizen study on conflicts of interest, and a negative report from the National Research Center for Women and Families (1"The Pink Sheet" Sept. 11, 2006, p. 22)...
You may also be interested in...
FDA Considering New Metrics To Evaluate Advisory Panel Member Conflicts
In response to concerns about conflicts of interests involving advisory committee members, FDA has started to examine possible metrics to assess panelists' expertise and relationships with regulated companies
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.